Product Images Simvastatin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Simvastatin NDC 71335-1891 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Footnote for Table 3 - Footnote for Table 3
This document discusses the results of a chemical assay related to the effects of certain inhibitors (such as Ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone) on the drug Simvastatin. It also mentions the presence of Simvastatin acid, as well as the lack of research regarding the impact of different amounts of grapefruit juice on Simvastatin pharmacokinetics. The document also provides information on the dosages and timing of grapefruit juice and Simvastatin administration during the study.*
Label - lbl713351891
This appears to be a label for a prescription bottle of Simvastatin, a medication used to control cholesterol levels. The label provides information such as the strength of each tablet (20mg), storage instructions, and the expiration date. The medication is to be kept out of reach of children.*
Figure 9 - simvastatin 10
table2 - simvastatin 2
This is a table showing the adverse reactions reported by patients treated with Simvastatin and Placebo. The table includes the percentage of patients experiencing adverse reactions in various body systems. Some of the adverse reactions reported include edema and swelling, abdominal pain, atrial fibrillation, constipation, myalgia, headache, insomnia, vertigo, bronchitis, sinusitis, eczema, and urinary tract infection.*
Structure - simvastatin 3
table 3 - simvastatin 4
table 4 - simvastatin 5
Figure 5 - simvastatin 6
This is a medical study analyzing the efficacy of Simvastatin in preventing major vascular and coronary events in patients with or without previous cardiovascular health issues. The study involved a total of 20,858 patients, with varying degrees of peripheral and coxaezovascular diseases. The text is mostly presented in the form of a table, which includes data on the number of patients with and without cHD, their respective treatments with Simvastatin and Placebo, and their corresponding risk ratios for major vascular and coronary events.*
Figure 6 - simvastatin 7
Figure 7 - simvastatin 8
Figure 8 - simvastatin 9
table 1 - table1
The text is discussing drug interactions that are associated with an increased risk of myopathy/rhabdomyolysis. It lists a number of interacting agents and provides prescribing recommendations for each. The interactions include strong CYP3A4 inhibitors, HIV protease inhibitors, niacin, verapamil, diltiazem, amiodarone, and others. Patients with HOFH are cautioned not to exceed certain doses, and individuals taking certain medications are advised to avoid grapefruit juice. The last line is an error and is not available.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.